All patients
age >= 60 yr age >= 65 yr corticosteroids: no corticosteroids: yes invasive ventilation non invasive oxygen subjects at risk
antiviral and associated therapy in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24]
Mobarak (DISCOVER), 2021 1.15 [0.83; 1.59]
Mobarak S (DISCOVER), 2021 1.10 [0.77; 1.57]
NIH NIAID ACTT-1, 2020 0.73 [0.52; 1.03]
Silva, 2021 0.46 [0.03; 8.02]
0.94 [0.76 ; 1.16 ] HYDRA (Hernandez-Cardenas), 2021, Mobarak (DISCOVER), 2021, Mobarak S (DISCOVER), 2021, NIH NIAID ACTT-1, 2020, Silva, 2021 5 22% 3,482 low not evaluable deathsdetailed results CAP-China (Wang et al.), 2020 1.10 [0.49; 2.45]
Gonzalez (HCQ), 2020 0.33 [0.06; 1.78]
Gonzalez (IVER), 2020 0.83 [0.23; 3.02]
HYCOVID, 2020 0.54 [0.21; 1.40]
HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24]
Kirti, 2021 0.12 [0.01; 2.36]
Mobarak (DISCOVER), 2021 1.15 [0.83; 1.59]
Mobarak S (DISCOVER), 2021 1.15 [0.80; 1.67]
NCT04342650, 2020 0.95 [0.02; 48.42]
NIH NIAID ACTT-1, 2020 0.55 [0.36; 0.84]
ORCHID, 2020 1.07 [0.54; 2.11]
Patel, 2021 0.77 [0.11; 5.34]
ProPAC-COVID, 2021 0.08 [0.00; 8.65]
RIVET-COV (Mohan) (12mg and 24mg), 2021 0.52 [0.01; 26.47]
Rocco, 2020 1.02 [0.02; 51.70]
Shenoy S, 2021 1.32 [0.58; 2.99]
TEACH, 2020 1.07 [0.34; 3.37]
0.92 [0.77 ; 1.09 ] CAP-China (Wang et al.), 2020, Gonzalez (HCQ), 2020, Gonzalez (IVER), 2020, HYCOVID, 2020, HYDRA (Hernandez-Cardenas), 2021, Kirti, 2021, Mobarak (DISCOVER), 2021, Mobarak S (DISCOVER), 2021, NCT04342650, 2020, NIH NIAID ACTT-1, 2020, ORCHID, 2020, Patel, 2021, ProPAC-COVID, 2021, RIVET-COV (Mohan) (12mg and 24mg), 2021, Rocco, 2020, Shenoy S, 2021, TEACH, 2020 17 2% 5,986 low low deaths (time to event analysis only)detailed results HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24]
NIH NIAID ACTT-1, 2020 0.55 [0.36; 0.84]
0.66 [0.46 ; 0.95 ] HYDRA (Hernandez-Cardenas), 2021, NIH NIAID ACTT-1, 2020 2 32% 1,276 moderate not evaluable clinical deteriorationdetailed results CAP-China (Wang et al.), 2020 0.95 [0.55; 1.64]
RIVET-COV (Mohan) (12mg and 24mg), 2021 0.53 [0.15; 1.95]
Rocco, 2020 1.02 [0.29; 3.58]
TEACH, 2020 1.80 [0.62; 5.21]
1.00 [0.65 ; 1.53 ] CAP-China (Wang et al.), 2020, RIVET-COV (Mohan) (12mg and 24mg), 2021, Rocco, 2020, TEACH, 2020 4 0% 882 moderate not evaluable clinical improvementdetailed results CAP-China (Wang et al.), 2020 1.23 [0.87; 1.74]
NIH NIAID ACTT-1, 2020 1.29 [1.12; 1.49]
ORCHID, 2020 1.02 [0.73; 1.42]
Rocco, 2020 0.81 [0.52; 1.27]
1.14 [0.95 ; 1.37 ] CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 2020, ORCHID, 2020, Rocco, 2020 4 39% 2,170 moderate not evaluable clinical improvement (14-day)detailed results CAP-China (Wang et al.), 2020 1.21 [0.64; 2.28]
ORCHID, 2020 1.02 [0.73; 1.42]
1.06 [0.79 ; 1.42 ] CAP-China (Wang et al.), 2020, ORCHID, 2020 2 0% 715 low not evaluable clinical improvement (28-day)detailed results CAP-China (Wang et al.), 2020 1.37 [0.79; 2.39]
NIH NIAID ACTT-1, 2020 1.35 [1.03; 1.76]
ORCHID, 2020 0.97 [0.69; 1.37]
1.21 [0.97 ; 1.51 ] CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 2020, ORCHID, 2020 3 17% 1,777 moderate not evaluable clinical improvement (7-day)detailed results CAP-China (Wang et al.), 2020 0.99 [0.18; 5.51]
Kirti, 2021 0.90 [0.77; 1.06]
ORCHID, 2020 1.16 [0.84; 1.61]
Rocco, 2020 0.81 [0.52; 1.27]
0.93 [0.81 ; 1.07 ] CAP-China (Wang et al.), 2020, Kirti, 2021, ORCHID, 2020, Rocco, 2020 4 0% 1,219 moderate not evaluable clinical improvement (time to event analysis only)detailed results CAP-China (Wang et al.), 2020 1.23 [0.87; 1.74]
HYDRA (Hernandez-Cardenas), 2021 1.05 [0.74; 1.48]
NIH NIAID ACTT-1, 2020 1.29 [1.12; 1.49]
ORCHID, 2020 0.97 [0.69; 1.36]
Shenoy S, 2021 0.99 [0.77; 1.28]
Shinkai, 2021 1.40 [0.91; 2.15]
Wu X, 2020 2.00 [0.71; 5.66]
1.18 [1.05 ; 1.32 ] CAP-China (Wang et al.), 2020, HYDRA (Hernandez-Cardenas), 2021, NIH NIAID ACTT-1, 2020, ORCHID, 2020, Shenoy S, 2021, Shinkai, 2021, Wu X, 2020 7 10% 2,980 moderate not evaluable death or ventilationdetailed results Gonzalez (HCQ), 2020 0.69 [0.22; 2.21]
Gonzalez (IVER), 2020 0.89 [0.30; 2.64]
HYCOVID, 2020 1.12 [0.45; 2.79]
ORCHID, 2020 1.13 [0.60; 2.13]
1.01 [0.65 ; 1.57 ] Gonzalez (HCQ), 2020, Gonzalez (IVER), 2020, HYCOVID, 2020, ORCHID, 2020 4 0% 867 moderate not evaluable hospital dischargedetailed results Gonzalez (HCQ), 2020 1.38 [0.46; 4.16]
Gonzalez (IVER), 2020 0.71 [0.15; 3.40]
HYDRA (Hernandez-Cardenas), 2021 1.01 [0.72; 1.42]
Kirti, 2021 1.20 [0.73; 1.98]
Mobarak (DISCOVER), 2021 1.01 [0.95; 1.08]
Patel, 2021 0.57 [0.12; 2.68]
RIVET-COV (Mohan) (12mg and 24mg), 2021 2.31 [0.66; 8.04]
Shenoy S, 2021 1.06 [0.85; 1.32]
1.02 [0.96 ; 1.08 ] Gonzalez (HCQ), 2020, Gonzalez (IVER), 2020, HYDRA (Hernandez-Cardenas), 2021, Kirti, 2021, Mobarak (DISCOVER), 2021, Patel, 2021, RIVET-COV (Mohan) (12mg and 24mg), 2021, Shenoy S, 2021 8 0% 2,490 NA not evaluable hospitalizationdetailed results EPIC-SR, 0 0.29 [0.08; 1.07]
Holubar M, 2021 0.12 [0.01; 2.26]
0.25 [0.08 ; 0.83 ] EPIC-SR, 0, Holubar M, 2021 2 0% 1,003 NA not evaluable mechanical ventilationdetailed results Kirti, 2021 0.20 [0.00; 8.69]
Mobarak S (DISCOVER), 2021 1.52 [0.72; 3.19]
RIVET-COV (Mohan) (12mg and 24mg), 2021 0.52 [0.01; 26.47]
1.36 [0.67 ; 2.79 ] Kirti, 2021, Mobarak S (DISCOVER), 2021, RIVET-COV (Mohan) (12mg and 24mg), 2021 3 0% 1,347 moderate not evaluable viral clearance detailed results Chaccour, 2020 0.92 [0.77; 1.09]
Holubar M, 2021 0.76 [0.48; 1.20]
RIVET-COV (Mohan) (12mg and 24mg), 2021 1.10 [0.50; 2.39]
0.91 [0.77 ; 1.06 ] Chaccour, 2020, Holubar M, 2021, RIVET-COV (Mohan) (12mg and 24mg), 2021 3 0% 287 low not evaluable viral clearance (time to event analysis only)detailed results Ahmed, 2020 4.10 [1.12; 14.99]
Holubar M, 2021 0.76 [0.48; 1.20]
1.58 [0.31 ; 8.10 ] Ahmed, 2020, Holubar M, 2021 2 83% 221 low not evaluable viral clearance by day 14detailed results Ahmed, 2020 4.10 [1.12; 14.99]
4.10 [1.12 ; 14.99 ] Ahmed, 2020 1 0% 72 NA not evaluable viral clearance by day 7detailed results Chaccour, 2020 0.92 [0.77; 1.09]
Kirti, 2021 0.80 [0.43; 1.50]
RIVET-COV (Mohan) (12mg and 24mg), 2021 1.10 [0.50; 2.39]
0.92 [0.78 ; 1.08 ] Chaccour, 2020, Kirti, 2021, RIVET-COV (Mohan) (12mg and 24mg), 2021 3 0% 250 low not evaluable ICU admissiondetailed results Kirti, 2021 0.90 [0.30; 2.70]
ProPAC-COVID, 2021 1.24 [0.26; 5.80]
Rocco, 2020 4.11 [0.18; 91.83]
1.12 [0.47 ; 2.64 ] Kirti, 2021, ProPAC-COVID, 2021, Rocco, 2020 3 0% 621 moderate not evaluable off oxygenationdetailed results HYDRA (Hernandez-Cardenas), 2021 0.98 [0.64; 1.51]
0.98 [0.64 ; 1.51 ] HYDRA (Hernandez-Cardenas), 2021 1 0% 214 NA not evaluable recoverydetailed results Mobarak S (DISCOVER), 2021 0.97 [0.89; 1.05]
0.97 [0.89 ; 1.05 ] Mobarak S (DISCOVER), 2021 1 0% 1,083 NA not evaluable AE leading to drug discontinuationdetailed results CAP-China (Wang et al.), 2020 2.43 [0.79; 7.45]
2.43 [0.79 ; 7.45 ] CAP-China (Wang et al.), 2020 1 0% 233 NA not evaluable serious adverse eventsdetailed results CAP-China (Wang et al.), 2020 0.64 [0.33; 1.23]
NIH NIAID ACTT-1, 2020 0.72 [0.54; 0.96]
ORCHID, 2020 1.26 [0.56; 2.84]
RIVET-COV (Mohan) (12mg and 24mg), 2021 0.52 [0.01; 26.47]
Shinkai, 2021 2.80 [0.14; 56.95]
0.75 [0.59 ; 0.96 ] CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 2020, ORCHID, 2020, RIVET-COV (Mohan) (12mg and 24mg), 2021, Shinkai, 2021 5 0% 2,083 moderate not evaluable adverse eventsdetailed results Chaccour, 2020 1.00 [0.20; 5.07]
Holubar M, 2021 2.07 [0.89; 4.83]
ORCHID, 2020 1.42 [0.87; 2.34]
RIVET-COV (Mohan) (12mg and 24mg), 2021 1.25 [0.45; 3.47]
Shinkai, 2021 19.54 [7.77; 49.11]
TEACH, 2020 1.16 [0.55; 2.42]
2.14 [0.93 ; 4.91 ] Chaccour, 2020, Holubar M, 2021, ORCHID, 2020, RIVET-COV (Mohan) (12mg and 24mg), 2021, Shinkai, 2021, TEACH, 2020 6 83% 1,085 low not evaluable deep vein thrombosisdetailed results CAP-China (Wang et al.), 2020 0.50 [0.03; 8.10]
NIH NIAID ACTT-1, 2020 0.64 [0.23; 1.81]
0.62 [0.23 ; 1.64 ] CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 2020 2 0% 1,296 moderate not evaluable elevated liver enzymesdetailed results CAP-China (Wang et al.), 2020 0.36 [0.13; 1.01]
NIH NIAID ACTT-1, 2020 0.67 [0.38; 1.18]
0.58 [0.34 ; 0.97 ] CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 2020 2 6% 1,296 moderate not evaluable hyperbilirubinemiadetailed results CAP-China (Wang et al.), 2020 1.09 [0.42; 2.79]
NIH NIAID ACTT-1, 2020 0.84 [0.30; 2.34]
0.97 [0.48 ; 1.93 ] CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 2020 2 0% 1,296 low not evaluable pulmonary embolismdetailed results CAP-China (Wang et al.), 2020 0.50 [0.03; 8.10]
NIH NIAID ACTT-1, 2020 0.96 [0.19; 4.80]
0.82 [0.20 ; 3.29 ] CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 2020 2 0% 1,296 moderate not evaluable renal impairmentdetailed results CAP-China (Wang et al.), 2020 1.01 [0.03; 30.33]
NIH NIAID ACTT-1, 2020 1.02 [0.64; 1.61]
1.02 [0.64 ; 1.61 ] CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 2020 2 0% 1,296 moderate not evaluable severe adverse eventsdetailed results Patel, 2021 1.21 [0.02; 64.67]
1.21 [0.02 ; 64.67 ] Patel, 2021 1 0% 33 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-03 23:43 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 95,94,90,91
- treatments: 545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814
- roots T: 290
